In medical news:

The FDA delivered its second guidance measure on opioids in the last week, issuing new rules on the development of generic versions of abuse-deterrent formulations. Once finalized, the latest guidance will be designed to ensure that abuse-deterrent mechanisms in generic opioids are as effective as their branded counterparts. The 31-page document outlines the studies and data formats manufacturers should use to satisfy the agency that a generic opioid is equivalently abuse-deterrent. Guidance documents are not binding, but most companies follow them because they spell out the FDA’s preferences on regulated products.

Read further coverage from MedPage Today here. Read the FDA guidance in full here.

Leave a Comment

Your email address will not be published. Required fields are marked *